This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

lomitapide (Lojuxta®)

Reference No. 1182

Publication date:

Appraisal information

lomitapide (Lojuxta®) 5 mg capsule
lomitapide (Lojuxta®) 10 mg capsule
lomitapide (Lojuxta®) 20 mg capsule

Company: Aegerion Pharmaceuticals Ltd
BNF category: Cardiovascular system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 06/12/2013

Current Progress

Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, lomitapide (Lojuxta®) cannot be endorsed for use within NHS Wales in adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolaemia (HoFH). Genetic confirmation of HoFH should be obtained whenever possible. Other forms of primary hyperlipoproteinemia and secondary causes of hypercholesterolemia (e.g., nephrotic syndrome, hypothyroidism) must be excluded.
Statement of Advice (SOA)